Clinical Trial: Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07104565) titled 'Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders' on July 29.

Brief Summary: This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.

Study Start Date: Oct. 15

Study Type: INTERVENTIONAL

Condition: Immune Thrombocytopenia

Intervention: DRUG: INCA000585

Tafasitamab will be administered intravenously at protocol defined timepoints.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Incyte Corporation

Disclaimer: Curated by HT Syndication....